Literature DB >> 401675

Monoclonal macroglobulinemia with osteolytic lesions: a case report and review of the literature.

L Leb, E T Grimes, K Balogh, J A Merritt.   

Abstract

A patient with monoclonal macroglobulinemia and osteolytic lesions was studied and 24 previously reported closely related cases were reviewed. Cases studied by ultracentrifugation without an immunoelectrophoresis were not considered. Patients presenting with a primary increase in monoclonal IgM molecules may be divided into three groups: typical Waldenstrom's macroglobulinemia, macroglobulinemia with osteolytic lesions resembling multiple myeloma, and a group displaying features of both diseases. At present, cell morphology is not helpful in separating these groups, and a bone survey is recommended. The authors underscore the clinical importance of the early recognition of these entities since procedures such as plasmapheresis for the management of hyperviscosity syndrome, mobilization and local radiotherapy to symptomatic lytic lesions may be necessary for optimal management.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 401675     DOI: 10.1002/1097-0142(197701)39:1<227::aid-cncr2820390136>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

Review 1.  Malignant lymphomas--a conceptual understanding of morphologic diversity. A review.

Authors:  R B Mann; E S Jaffe; C W Berard
Journal:  Am J Pathol       Date:  1979-01       Impact factor: 4.307

2.  Polyclonal B-cell activation induced by extracts of Gram-negative bacteria isolated from periodontally diseased sites.

Authors:  P H Bick; A B Carpenter; L V Holdeman; G A Miller; R R Ranney; K G Palcanis; J G Tew
Journal:  Infect Immun       Date:  1981-10       Impact factor: 3.441

3.  Waldenstrom's macroglobulinemia presenting with lytic bone lesions: a rare presentation.

Authors:  Mukta Pujani; Shivani Kushwaha; Neha Sethi; Anu Beniwal; Shailaja Shukla
Journal:  Blood Res       Date:  2013-09-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.